The local medical insurance reimbursement rate of domestic new crown drugs reaches 95%, and the maximum self-payment is as low as 30 yuan

Author: Qian Tongxin

With the normalization of new crown epidemic prevention, the stockpiling and use of new crown drugs has become more popular. The first financial reporter recently learned from the Nanjing Municipal Medical Security Bureau that according to the latest medical insurance reimbursement policy, domestic new crown drugs can be paid at most as low as 30 yuan.

According to a notice issued by the Nanjing Municipal Medical Security Bureau on the Payment Scope of Basic Medical Boils Insurance for Temporary Admission of New Crown Treatment Drugs and the Adjustment of the Payment Ratio of Some Drugs, the proportion of self-payment for the domestically produced new crown drug Xiannoxin (prenortevir/ritonavir combination packaging) is 5% for individuals, and 10% for Mindevi and Leruling.

Specifically, taking Xiannoxin, which has the highest medical insurance reimbursement ratio, as an example, its price is 630 yuan / box, and the individual pays 5% first, that is, 31.5 yuan, and the remaining 95% reimbursement ratio is determined according to whether the patient is hospitalized, age, whether he is in the job, etc., ranging from 30% to 100%.

Chen Chong, a first-level director of the Medical Service Management Division of Nanjing Medical Security Bureau, told First Financial Reporter in an interview with the media that this new policy can reduce the drug burden of the people, meet their drug needs, and improve the accessibility of new crown drugs.

On March 3 this year, the National Health Insurance Administration issued the Notice on Improving the Price Formation Mechanism of New Crown Treatment Drugs and Implementing Classified Management, which allows a number of domestic antiviral drugs to enjoy temporary medical insurance payment, and each region stipulates the reimbursement ratio according to the actual situation.

Pfizer's Paxlovid (nematevir/ritonavir tablets) after the expiration of the temporary medical insurance policy this year, the current price in public hospitals is 1890 yuan / box, and the price of non-public medical institutions is 2170 yuan / box, all of which need to be paid by themselves.

Since the beginning of this year, the state has specially approved three domestic new crown innovative drugs for marketing. Synoxin and Paxlovid and the two drugs are antiviral drugs developed with 3CL as the target, and both are included in the "Diagnosis and Treatment Protocol for Novel Coronavirus Infection (Trial Version <>)".

At the peak of the first wave of coronavirus positives, many patients could only use symptomatic traditional cold medicines such as ibuprofen. Simcere Pharmaceutical, a manufacturer of Xiannoxin, responded to the first financial reporter: "Xiannoxin's production capacity has passed the climbing period, and now there is no problem with our drug production capacity guarantee, and patients can use more antiviral drugs." ”

The new crown variant currently circulating in China is XBB, is the previously developed new crown antiviral drug still effective? In this regard, Professor Wang Guiqiang, director of the Department of Infectious Diseases of Peking University First Hospital, said: "The highly conservative characteristics of the 3CL target are still effective against the XBB variant."